Ligand (LGND) | Stock Overview & Key Data
Ligand Performance Comparison
Stock Range
Today's Range
Low: $156.91
High: $161.93
on August 22, 2025
52 Week Range
Low: $93.58
High: $161.93
on April 9, 2025
on August 22, 2025
All-Time High: $173.81 on October 1, 2018
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$3.1B
EPS
-4.04
P/E Ratio (TTM)
46.27
Forward P/E
26.31
P/B Ratio
3.69
PEG Ratio
-0.43
Div. Yield
N/A
ROE
-9.46%
Beta
0.740
Debt to Equity
0.69
Financial Highlights
Profitability
Gross Margin
93.90%
Operating Margin
20.41%
Profit Margin
-40.44%
Returns and Earnings
Return on Assets (TTM)
-0.99%
Return on Equity (TTM)
-9.46%
EBITDA
$11.4M
Net Income (TTM)
$-75.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$9.82
Quarterly Revenue Growth (YoY)
14.70%
Quarterly Earnings Growth (YoY)
14.68%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Ligand LGND | 3.07B Mid-cap | 5.30% | 20.10% | 57.05% | 35.88% | 46.73% | 53.23% | 158.29% | 146.98% |
| Vertex VRTX | 101.31B Large-cap | 0.59% | -15.96% | -8.96% | -17.97% | -2.62% | -17.90% | 40.27% | 46.36% |
| Regeneron REGN | 63.57B Large-cap | 1.56% | 5.09% | -1.23% | -17.35% | -17.58% | -50.84% | -1.12% | -2.18% |
| BridgeBio Pharma BBIO | 9.38B Mid-cap | -4.36% | 7.23% | 48.86% | 35.39% | 74.04% | 93.92% | 368.32% | 65.87% |
| Madrigal MDGL | 9.07B Mid-cap | 12.12% | 32.32% | 51.70% | 28.73% | 32.16% | 64.07% | 491.89% | 288.86% |
| Halozyme HALO | 8.38B Mid-cap | 6.76% | 24.82% | 33.62% | 22.77% | 49.59% | 14.51% | 78.26% | 152.53% |
Ownership & Short Interest
Insider Ownership
2.31%
Institutional Ownership
100.25%
Shares Short
916K
Short Ratio
5.17
Short % of Shares Outstanding
5.71%
Average 10-Day Volume
441K
Average 90-Day Volume
286K
Ligand Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Ligand would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is LGND's 52-week high and low?
- In the last 52 weeks, Ligand reached a high of $161.93 (on August 22, 2025) and a low of $93.58 (on April 9, 2025).
- What is the market cap and P/E ratio for LGND?
- Curious about Ligand's size and valuation? Its market capitalization stands at 3.07B. When it comes to valuation, the P/E ratio (trailing twelve months) is 46.27, and the forward P/E (looking ahead) is 26.31.
- Does LGND pay dividends? If so, what's the yield?
- As for dividends, Ligand isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Ligand's main competitors or similar companies to consider before investing?
When looking at Ligand, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX101.31B Healthcare Biotechnology -17.90% 40.27% Regeneron
REGN63.57B Healthcare Biotechnology -50.84% -1.12% BridgeBio Pharma
BBIO9.38B Healthcare Biotechnology 93.92% 368.32% Madrigal
MDGL9.07B Healthcare Biotechnology 64.07% 491.89% Halozyme
HALO8.38B Healthcare Biotechnology 14.51% 78.26% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ligand Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Ligand's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -9.46%, the Debt to Equity ratio from the most recent quarter is 0.69, and its Gross Profit Margin stands at 93.90%.
- What is the recent revenue and earnings growth for LGND?
- Looking at Ligand's growth, its revenue over the trailing twelve months (TTM) was $188M. Compared to the same quarter last year (YoY), quarterly revenue grew by 14.70%, and quarterly earnings saw a YoY growth of 14.68%.
- How much of LGND stock is held by insiders and institutions?
- Wondering who owns Ligand stock? Company insiders (like executives and directors) hold about 2.31% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 100.25%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.